Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer

Use of the inhibitor of ALK fusion onco-protein, crizotinib (PF02341066), has achieved impressive clinical efficacy in patients with ALK-positive non-small cell lung cancer. Nevertheless, acquired resistance to this drug occurs inevitably in approximately a year, limiting the therapeutic benefits of...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Ji, Cheng, Zhang, Li, Cheng, Yan, Patel, Raj, Wu, Hao, Zhang, Yi, Wang, Mian, Ji, Shundong, Belani, Chandra P, Yang, Jin-Ming, Ren, Xingcong
Médium: Artigo
Jazyk:Inglês
Vydáno: Landes Bioscience 2014
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4026079/
https://ncbi.nlm.nih.gov/pubmed/24556908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.28162
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky